The abrogation of the HOXB7/PBX2 complex induces apoptosis in melanoma through the miR-221&222-c-FOS pathway

International Journal of Cancer

Volumn 133, Issue 4, 2013, Pages 879-892

  Errico, M Cristina ^a   Felicetti, Federica ^a   Bottero, Lisabianca ^a   Mattia, Gianfranco ^a   Boe, Alessandra ^a   Felli, Nadia ^a   Petrini, Marina ^a   Bellenghi, Maria ^a   Pandha, Hardev S ^b   Calvaruso, Marco ^c   Tripodo, Claudio ^c   Colombo, Mario P ^d   Morgan, Richard ^b   Carè, Alessandra ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b UNIVERSITY OF SURREY   (United Kingdom)

^c UNIVERSITY OF PALERMO   (Italy)

^d NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

HOXB7; HXR9 peptide; melanoma; microRNA; PBX

Indexed keywords

HXR9 PEPTIDE; MICRORNA 221; MICRORNA 222; PEPTIDE; PROTEIN C FOS; PROTEIN HOXB7; PROTEIN PBX2; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; CUTANEOUS MELANOMA; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN TISSUE; MELANOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; TRANSCRIPTION REGULATION;

APOPTOSIS; BASE SEQUENCE; CELL LINE, TUMOR; DIMERIZATION; DNA PRIMERS; HOMEODOMAIN PROTEINS; HUMANS; MELANOMA; MICRORNAS; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-FOS; RNA, SMALL INTERFERING; SKIN NEOPLASMS; TRANSCRIPTION, GENETIC;

EID: 84878862650     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28097     Document Type: Article

References (41)

1. Whiteman DC, Pavan WJ, Bastian BC,. The melanomas: a synthesis of epidemiological, clinical, histopathological, genetic, and biological aspects, supporting distinct subtypes, causal pathways, and cells of origin. Pigment Cell Melanoma Res 2011; 24: 879-97.
2. Nilay S, Saraswati S,. The Hox genes and their roles in oncogenesis. Nat Rev Cancer 2010; 10: 361-71.
3. Abate-Shen C,. Deregulated homeobox gene expression in cancer: cause or consequence? Nat Rev Cancer 2002; 2: 777-85. (Pubitemid 37328912)
4. Henderson GS, van Diest PJ, Burger H, et al. Expression pattern of a homeotic gene, HOXA5, in normal breast and in breast tumors. Cell Oncol 2006; 28: 305-13. (Pubitemid 44950101)
5. Chu MC, Selam FB, Taylor HS,. HOXA10 regulates p53 expression and matrigel invasion in human breast cancer cells. Cancer Biol Ther 2004; 3: 568-72. (Pubitemid 41351131)
6. deBlacam C, Byrne C, Hughes E, et al. HOXC11-SRC-1 regulation of S100beta in cutaneous melanoma: new targets for the kinase inhibitor dasatinib. Br J Cancer 2011; 105: 118-23.
7. Carè A, Felicetti F, Meccia E, et al. HOXB7: a key factor for tumor-associated angiogenic switch. Cancer Res 2001; 61: 6532-9. (Pubitemid 32783261)
8. Caré A, Silvani A, Meccia E, et al. HOXB7 constitutively activates basic fibroblast growth factor in melanomas. Mol Cell Biol 1996; 16: 4842-51. (Pubitemid 26272139)
9. Fernandez LC, Errico MC, Bottero L, et al. Oncogenic HoxB7 requires TALE cofactors and is inactivated by a dominant-negative PBX1 mutant in a cell-specific manner. Cancer Lett 2008; 266: 144-55.
10. Morgan R, In der Rieden P, Hooiveld MH, et al. Identifying HOX paralog groups by the PBX-binding region. Trends Genet 2000; 16: 66-7. (Pubitemid 30084718)
11. Chang CP, Brocchieri L, Shen WF, et al. Pbx modulation of Hox homeodomain amino-terminal arms establishes different DNA-binding specificities across the Hox locus. Mol Cell Biol. 1996; 16: 1734-45. (Pubitemid 26095646)
12. Morgan R, Pirard PM, Shears L, et al. Antagonism of HOX/PBX dimer formation blocks the in vivo proliferation of melanoma. Cancer Res 2007; 67: 5806-13. (Pubitemid 46985014)
13. Shears L, Plowright L, Harrington K, et al. Disrupting the interaction between HOX and PBX causes necrotic and apoptotic cell death in the renal cancer lines CaKi-2 and 769-P. J Urol 2008; 180: 2196-201.
14. Morgan R, Plowright L, Harrington KJ, et al. Targeting HOX and PBX transcription factors in ovarian cancer. BMC Cancer 2010; 10: 89.
15. Plowright L, Harrington KJ, Pandha HS, et al. HOX transcription factors are potential therapeutic targets in non-small-cell lung cancer (targeting HOX genes in lung cancer). Br J Cancer 2009; 100: 470-5.
16. Nana-Sinkam SP, Croce CM,. MicroRNAs as therapeutic targets in cancer. Transl Res 2011; 157: 216-25.
17. Garofalo M, Di Leva G, Romano G, et al MiR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation. Cancer Cell 2009; 6: 498-509.
18. Felicetti F, Errico MC, Bottero L, et al. The promyelocytic zinc finger-microRNA-221/-222 pathway controls melanoma progression through multiple oncongenic mechanisms. Cancer Res 2008; 68: 2745-54. (Pubitemid 351556272)
19. Subramanian S, Steer CJ,. MicroRNAs as gatekeepers of apoptosis. J Cell Physiol 2010; 223: 289-98.
20. Kozlowski JM, Hart IR, Fidler IJ, et al. A human melanoma line heterogeneous with respect to metastatic capacity in athymic nude mice. J Natl Cancer Inst 1984, 72: 913-7. (Pubitemid 14131734)
21. Mattia G, Errico MC, Felicetti F, et al. Constitutive activation of the ETS-1-miR-222 circuitry in metastatic melanoma. Pigment Cell Melanoma Res 2011; 24: 953-65.
22. Monje P, Hernández-Losa J, Lyons RJ, et al. Regulation of the transcriptional activity of c-Fos by ERK. A novel role for the prolyl isomerase PIN1. J Biol Chem 2005; 280: 35081-4. (Pubitemid 41532693)
23. Ferrara P, Andermarcher E, Bossis G, et al. The structural determinants responsible for c-Fos protein proteasomal degradation differ according to the conditions of expression. Oncogene. 2003; 22: 1461-74. (Pubitemid 36390595)
24. Chen RH, Juo PC, Curran T, et al. Phosphorylation of c-Fos at the C-terminus enhances its transforming activity. Oncogene 1996; 12: 1493-502. (Pubitemid 26132036)
25. Solit DB, Rosen N,. Resistance to BRAF inhibition in melanomas. N Engl J Med 2011; 364: 772-4.
26. Li W, Zhang X, Olumi AF,. MG-132 sensitizes TRAIL-resistant prostate cancer cells by activating c-Fos/c-Jun heterodimers and repressing c-FLIP(L). Cancer Res 2007; 67: 2247-55. (Pubitemid 46424244)
27. Wu X, Chen H, Parker B, et al. HOXB7, a homeodomain protein, is overexpressed in breast cancer and confers epithelial-mesenchymal transition. Cancer Res 2006; 66: 9527-34. (Pubitemid 44623651)
28. Liao WT, Jiang D, Yuan J, et al. HOXB7 as a prognostic factor and mediator of colorectal cancer progression. Clin Cancer Res 2011; 17: 3569-78.
29. Bitu CC, Carrera M, Lopes MA, et al. HOXB7 expression is a prognostic factor for oral squamous cell carcinoma. Histopathology 2012; 60: 662-5.
30. le Sage C, Nagel R, Egan DA, et al. Regulation of the p27(Kip1) tumor suppressor by miR-221 and miR-222 promotes cancer cell proliferation. EMBO J 2007; 26: 3699-708. (Pubitemid 47236875)
31. Medina R, Zaidi SK, Liu CG, et al. MicroRNAs 221 and 222 bypass quiescence and compromise cell survival. Cancer Res 2008; 68: 2773-80. (Pubitemid 351556275)
32. Felicetti F, Bottero L, Felli N, et al. Role of PLZF in melanoma progression. Oncogene 2004; 23: 4567-76. (Pubitemid 38850404)
33. Hattori T, Ohoka N, Inoue Y, et al. C/EBP family transcription factors are degraded by the proteasome but stabilized by forming dimer. Oncogene. 2003; 22: 1273-80. (Pubitemid 36384589)
34. Longobardi E, Blasi F,. Overexpression of PREP-1 in F9 teratocarcinoma cells leads to a functionally relevant increase of PBX-2 by preventing its degradation. J Biol Chem 2003; 278: 39235-41. (Pubitemid 37221827)
35. Vasilescu J, Zweitzig DR, Denis NJ, et al. The proteomic reactor facilitates the analysis of affinity-purified proteins by mass spectrometry: application for identifying ubiquitinated proteins in human cells. J Proteome Res 2007; 6: 298-305. (Pubitemid 46173681)
36. Shaulian E, Karin M,. AP-1 as a regulator of cell life and death. Nat. Cell Biol 2002; 4: E131-6. (Pubitemid 34521026)
37. Zhang X, Zhang L, Yang H, et al. c-Fos as a proapoptotic agent in TRAIL induced apoptosis in prostate cancer cells. Cancer Res 2007; 67: 9425-34. (Pubitemid 47535933)
38. Lopez-Bergami P,. The role of mitogen- and stress-activated protein kinase pathways in melanoma. Pigment Cell Melanoma Res 2011; 24: 902-21.
39. Terasawa K, Ichimura A, Sato F, et al. Sustained activation of ERK1/2 by NGF induces microRNA-221 and 222 in PC12 cells. FEBS J 2009; 276: 3269-76.
40. Jin K, Kong X, Shah T, et al. The HOXB7 protein renders breast cancer cells resistant to tamoxifen through activation of the EGFR pathway. Proc Natl Acad Sci USA 2012; 109: 2736-41.
41. Garofalo M, Romano G, Di Leva G, et al. EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers. Nat Med 2011; 18: 74-82.